← Back to patent-cliff list

CAS 6974-32-9

(2S,3R,4R,5R)-2-acetoxy-5-((benzoyloxy)methyl)tetrahydrofuran-3,4-diyl dibenzoate

Codes: REGA-013, TRIC-002

Application context (from source-drug indications)

Cardiovascular contrast agentRegadenoson HydrateDiagnostic agentRegadenoson HydrateContrast imagingRegadenoson HydrateCoronary artery lesionRegadenoson HydrateIschaemic heart diseaseRegadenoson HydratePneumoniaRegadenoson HydrateLeukaemiaTriciribine PhosphateBreast cancerTriciribine PhosphateOvarian cancerTriciribine PhosphateHaematological malignancyTriciribine PhosphateSolid tumourTriciribine Phosphate

Source drugs (routes using this intermediate)

DrugTierExpiry
Regadenoson HydrateTier C — Watch / trade-
Triciribine PhosphateTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.